Cline, Davis & Mann launches CDM World Agency

Share this article:
Cline, Davis & Mann is going global with the launch of CDM World Agency, an international healthcare agency network with offices in Europe and Brazil and plans to expand into China, Japan, Mexico and Canada.

The global network will launch with offices in London, Paris, Munich, Barcelona, Madrid, Istanbul and Sao Paulo. CDM plans to open offices in China, Japan, Switzerland, Italy, Canada and Mexico this year. CDM World Agency will be headed by Eric Berkeley, who joined the network last year as director of global operations from DDB, where he held a similar role.

“For a long time, clients have been requiring that we have a global network,” said Cline, Davis & Mann chairman and CEO Ed Wise. “Now they are actually doing business that way. What clients are looking for is a higher level of control, and we wanted to elevate the network to be aligned along a single P&L and be a single agency around the world.”

Cline, Davis & Mann is headquartered in New York, with other US offices in Princeton, NJ, and Los Angeles.  

CDM has cobbled together the global offices over a year, with acquisitions of new*performance in Munich, Adding Targis in Madrid, Tagare in Sao Paulo, Intro in Istanbul and a merger in London.

Share this article:

Email Newsletters

More in News

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds